← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,342	+211	+10%	$231B
2	2 Danaher DHR $158B	2,082	+184	+10%	$186B
3	3 Novartis NVS $279B	1,146	+65	+6%	$18.5B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,078	+59	+6%	$56.9B
5	5 Illumina ILMN $41B	1,065	-8	-0.7%	$51.8B
6	6 Agilent Technologies A $49.1B	984	+41	+4%	$42.4B
7	7 Charles River Laboratories CRL $14.4B	707	+30	+4%	$17.8B
8	8 Revvity RVTY $17B	649	+39	+6%	$21.8B
9	9 DELISTED CATALENT, INC. CTLT	562	+33	+6%	$22.5B
10	10 ARK Genomic Revolution ETF ARKG $2.05B	462	-8	-2%	$1.4B
11	11 CRISPR Therapeutics CRSP $4.86B	446	-28	-6%	$3.27B
12	12 Alnylam Pharmaceuticals ALNY $30B	435	+30	+7%	$19B
13	13 Azenta AZTA $1.63B	401	+15	+4%	$7.27B
14	14 Guardant Health GH $21.9B	396	+22	+6%	$9.24B
15	15 Intellia Therapeutics NTLA $1.6B	372	+7	+2%	$7.64B
16	16 10x Genomics TXG $9.52B	365	+35	+11%	$11.9B
17	17 Sarepta Therapeutics SRPT $1.78B	344	+37	+12%	$6.48B
18	18 Ionis Pharmaceuticals IONS $7.1B	341	+16	+5%	$3.75B
19	NVTA 19 DELISTED Invitae Corporation NVTA	328	-23	-7%	$3.19B
20	20 Bruker BRKR $8.47B	327	+30	+10%	$8.99B
21	21 Arrowhead Research ARWR $8.25B	310	+13	+4%	$4.51B
22	22 Editas Medicine EDIT $349M	306	-14	-4%	$1.37B
23	23 Qiagen QGEN $9.41B	301	+36	+14%	$7.53B
24	24 Fulgent Genetics FLGT $578M	298	+30	+11%	$1.13B
25	25 Pacific Biosciences PACB $619M	255	+9	+4%	$4.2B